HKEX Stock Code: 01093
English
|
繁體
|
简体
Home
About Us
Products
News
Competence
Investor Relations
Contact Us
Corporate Profile
Corporate Information
Corporate Culture
Board of Directors
Corporate Governance
Products Overview
Finished Drugs
Bulk Drugs
Press Releases
Strategies
Quality
Research and Development
IR Overview
Financial Reports
Announcements & Notices
Circulars
Returns on Share Capital
Notice(s) of Replacement of Lost Share Certificates
Financial Calendar
Financial Summary
IR Contacts
Latest News
May
26
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 26 MAY 2022
May
25
QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2022
May
18
VOLUNTARY ANNOUNCEMENT - "DOXOFYLLINE INJECTION" OBTAINS DRUG REGISTRATION APPROVAL
/?php echo file_get_contents("https://www.irasia.com/cgi-local/adaptation/listco/hk/cspc/data.cgi?id=cspc&p=data&t=aclp&layout=home&n=3"); ?>
Financial Reports
2021 Annual Report
Highlight - 2021
Revenue
RMB27,867mn, +11.7%
Profit attributable to shareholders
RMB5,605mn, +8.6%
Basic earnings per share
RMB46.89 cents, +8.6%
Key Products
Finished drugs
Bulk drugs
NBP (soft capsules)
NBP (injections)
Oulaining (capsules)
Oulaining (lyophilised powder for injections)
Enxi
Duomeisu
Jinyouli
Keaili
Shuluoke
Nuomoling
Weihong
Xinweihong
Xuanning
Encun
Qixiao
Linmeixin
Shuanglexin
Gubang
Gubangjia
Gaoshunsong
Debixin
Qimaite
Antibiotics
Vitamin C
Caffeine